Search results for "Antineoplastic Agents"

showing 10 items of 1533 documents

Epithelial-mesenchymal transition: a new target in anticancer drug discovery

2016

The conversion of cells with an epithelial phenotype into cells with a mesenchymal phenotype, referred to as epithelial-mesenchymal transition, is a critical process for embryonic development that also occurs in adult life, particularly during tumour progression. Tumour cells undergoing epithelial-mesenchymal transition acquire the capacity to disarm the body's antitumour defences, resist apoptosis and anticancer drugs, disseminate throughout the organism, and act as a reservoir that replenishes and expands the tumour cell population. Epithelial-mesenchymal transition is therefore becoming a target of prime interest for anticancer therapy. Here, we discuss the screening and classification o…

0301 basic medicineAdultEpithelial-Mesenchymal TransitionCellPopulationAntineoplastic AgentsPharmacologyBiology03 medical and health sciences0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALENeoplasmsDrug DiscoverymedicineHumanscancerEpithelial–mesenchymal transitioneducationAdult; Antineoplastic Agents; Epithelial-Mesenchymal Transition; Humans; Neoplasms; Drug Discovery; Pharmacology; Drug Discovery3003 Pharmaceutical SciencePharmacologyeducation.field_of_studyTransition (genetics)Drug discoveryDrug Discovery3003 Pharmaceutical ScienceGeneral MedicineAnticancer drugEMT target therapy chemoresistance030104 developmental biologymedicine.anatomical_structureDrug developmentApoptosis030220 oncology & carcinogenesisCancer research
researchProduct

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

2019

Abstract Aims Most clinical trials exclude elderly people, leading to a limited understanding of the benefit-to-risk ratio in this population. Despite existing data regarding the oncological management of elderly receiving fluorouracil (5-FU)-based regimen, our objective was to investigate 5-FU exposure/toxicity relationship in patients ≥75 years and compare the effectiveness of 5-FU therapeutic drug monitoring between elderly and younger patients. Methods Hundred fifty-four patients (31 of whom are older than 75 years) with gastrointestinal cancers, who were to receive 5-FU–based regimens, were included in our study. At cycle 1 (C1), the 5-FU dose was calculated using patient's body surfac…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationAntineoplastic Agents03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGastrointestinal cancereducationAgedGastrointestinal NeoplasmsRetrospective StudiesBody surface areaAged 80 and overeducation.field_of_studymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryArea under the curveMiddle Agedmedicine.disease3. Good healthClinical trialRegimen030104 developmental biologyOncologyTolerabilityTherapeutic drug monitoring030220 oncology & carcinogenesisFemaleFluorouracilDrug MonitoringbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).

2017

Perivascular epithelioid cell tumors (PEComas) are infrequent neoplasms with peculiar myomelanocytic differentiation. The aggressive abdominopelvic variant is rare, with only a small number of published cases. We present an additional case of this unusual variant, which showed an aggressive histologic and clinical behavior with multiple liver metastases and resistance to several therapies. We also discuss the histological and immunohistochemical profiles as well as the differential diagnosis.

0301 basic medicineAdultPathologymedicine.medical_specialtyPerivascular Epithelioid Cell Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsDiseasePathology and Forensic MedicineTargeted therapy03 medical and health sciences0302 clinical medicineMedicineHumansMolecular Targeted TherapyChemotherapybusiness.industryTOR Serine-Threonine Kinasesmedicine.diseasePerivascular Epithelioid Cell Tumors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisImmunohistochemistrySurgeryFemaleSarcomaAnatomyDifferential diagnosisbusinessInternational journal of surgical pathology
researchProduct

Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs

2017

The discovery of the molecular mechanisms involved in the cardiac responses to anticancer drugs represents the current goal of cardio-oncology research. The oxidative stress has a pivotal role in cardiotoxic responses, affecting the function of all types of cardiac cells, and their functional crosstalks. Generally, cardiomyocytes are the main target of research studies on cardiotoxicity, but recently the contribution of the other nonmyocyte cardiac cells is becoming of growing interest. This review deals with the role of oxidative stress, induced by anticancer drugs, in cardiac nonmyocyte cells (fibroblasts, vascular cells, and immune cells). The alterations of functional interplays among t…

0301 basic medicineAgingHeart DiseasesAntineoplastic AgentsReview Article030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistryMuscle Smooth Vascular03 medical and health sciences0302 clinical medicineImmune systemHumansMedicineMyocytes CardiacLymphocyteslcsh:QH573-671Cardiotoxicitybusiness.industrylcsh:CytologyCell BiologyGeneral MedicineFibroblastsCell functionOxidative Stress030104 developmental biologyResearch studiesMolecular targetscardiovascular systemReactive Oxygen SpeciesbusinessOxidative stress
researchProduct

Chemoprevention and therapeutic role of essential oils and phenolic compounds: Modeling tumor microenvironment in glioblastoma

2021

Glioblastoma (GBM) is the most common primary tumor of the central nervous system. Current treatments available for GBM entails surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance and severe side effects. While this treatment could yield good results, in almost all cases, patients suffer from relapse, which leads to reduced survival rates. Thus, therapeutic approaches with improved efficiency and reduced off-target risks are needed to overcome these problems. Regarding this, natural products appear as a safe and attractive strategy as chemotherapeutic agents or adjuvants in the treatment of GBM. Besides the increasing …

0301 basic medicineAngiogenesismedicine.medical_treatmentAntineoplastic AgentsMetastasis03 medical and health sciences0302 clinical medicinePhenolsOils VolatileTumor MicroenvironmentAnimalsHumansMedicinePharmacologyBiological ProductsChemotherapyTumor microenvironmentTemozolomideBrain Neoplasmsbusiness.industrymedicine.diseasePrimary tumorRadiation therapy030104 developmental biology030220 oncology & carcinogenesisCancer researchNeoplasm Recurrence LocalStem cellGlioblastomabusinessmedicine.drugPharmacological Research
researchProduct

New Pharmacological Opportunities for Betulinic Acid

2017

AbstractBetulinic acid is a naturally occurring pentacyclic lupane-type triterpenoid usually isolated from birch trees, but present in many other botanical sources. It is found in different plant organs, both as a free aglycon and as glycosyl derivatives. A wide range of pharmacological activities has been described for this triterpenoid, including antiviral and antitumor effects. In addition, several other interesting properties have been identified in the fields of immunity and metabolism, namely antidiabetic, antihyperlipidemic, and anti-inflammatory activities. Taken together, these latter three properties make betulinic acid a highly interesting prospect for treating metabolic syndrome…

0301 basic medicineAnti-Inflammatory AgentsPharmaceutical ScienceAntineoplastic AgentsAntiviral AgentsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundTriterpenoidAnti-Infective AgentsBetulinic acidDrug DiscoveryAnimalsHumansHypoglycemic AgentsGlycosylBetulinic AcidDyslipidemiasHypolipidemic AgentsInflammationMetabolic SyndromePharmacologyNatural productTraditional medicineCytotoxinsOrganic ChemistryTriterpenes030104 developmental biologyDiabetes Mellitus Type 2Complementary and alternative medicinechemistryMolecular MedicinePentacyclic TriterpenesPentacyclic TriterpenesPlanta Medica
researchProduct

Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives

2017

1,2,3-Triazines are a class of biologically active compounds that exhibit a broad spectrum of activities, including antibacterial, antifungal, antiviral, antiproliferative, analgesic and anti-inflammatory properties. This review, which covers the literature from the end of last century to 2016, treats, through a comprehensive, systematic approach, the 1,2,3-triazine and related benzo- and hetero-fused derivatives possessing antitumor activity. Their efficacy, combined with a simple synthesis confers to these molecules a great potential as scaffold for the development of antitumor compounds.

0301 basic medicineAntifungalModels MolecularHetero-fused 1123-Triazines Benzo[123]triazines Hetero-fused 123-triazines Antiproliferative activity Antitumor activity Nitrogen heterocyclesStereochemistrymedicine.drug_class12Antineoplastic AgentsChemistry Techniques SyntheticAntiproliferative activity01 natural sciences03 medical and health sciencesBroad spectrumNeoplasmsDrug DiscoverymedicineBenzene DerivativesAnimalsHumans3]triazinesPharmacologyAntitumor activity3-triazines1; 2; 3-Triazines; Benzo[1; 2; 3]triazines; Hetero-fused 1; 2; 3-triazines; Antiproliferative activity; Antitumor activity; Nitrogen heterocyclesBenzo[1ChemistryTriazinesNitrogen heterocyclesOrganic ChemistryBiological activityGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaCombinatorial chemistry0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyAntitumor activity
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma

2020

Research for the most selective drug delivery to tumors represents a fascinating key target in science. Alongside the artificial delivery systems identified in the last decades (e.g., liposomes), a family of natural extracellular vesicles (EVs) has gained increasing focus for their potential use in delivering anticancer compounds. EVs are released by all cell types to mediate cell-to-cell communication both at the paracrine and the systemic levels, suggesting a role for them as an ideal nano-delivery system. Malignant pleural mesothelioma (MPM) stands out among currently untreatable tumors, also due to the difficulties in achieving an early diagnosis. Thus, early diagnosis and treatment of …

0301 basic medicineAntineoplastic AgentsReviewexosomesExtracellular vesiclesCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciencesdrug delivery systems0302 clinical medicinemedicineHumansexosomedrug delivery systemmalignant pleural mesotheliomaMesotheliomaPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyDrug Carriersbusiness.industryPleural mesotheliomaMesothelioma MalignantOrganic ChemistryGeneral Medicinemedicine.diseaseMicrovesiclesComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisDrug deliveryCancer researchDelivery systemextracellular vesiclebusinessextracellular vesicles
researchProduct

MicroRNA targeting by quercetin in cancer treatment and chemoprotection

2019

A growing number of evidences from clinical and preclinical studies have shown that dysregulation of microRNA (miRNA) function contributes to the progression of cancer and thus miRNA can be an effective target in therapy. Dietary phytochemicals, such as quercetin, are natural products that have potential anti-cancer properties due to their proven antioxidant, anti-inflammatory, and anti-proliferative effects. Available experimental studies indicate that quercetin could modulate multiple cancer-relevant miRNAs including let-7, miR-21, miR-146a and miR-155, thereby inhibiting cancer initiation and development. This paper reviews the data supporting the use of quercetin for miRNA-mediated chem…

0301 basic medicineAntineoplastic Agentsmedicine.disease_causeChemopreventionAntioxidants03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsDrug DiscoverymicroRNAAnimalsHumansMedicineEpigeneticsPharmacologyDrug discoverybusiness.industryChemoprotectionCancermedicine.diseaseBiomarker (cell)MicroRNAs030104 developmental biologychemistry030220 oncology & carcinogenesisCancer researchQuercetinQuercetinbusinessCarcinogenesisBiomarkersPharmacological Research
researchProduct